CABOXEN-80MG (Cabozantinib): Uses, Dosage, Side Effects & Cancer Treatment
CABOXEN-80MG (Cabozantinib): Uses, Dosage, Side Effects & Cancer Treatment
What Is CABOXEN-80MG?
CABOXEN-80MG contains cabozantinib, a targeted anticancer medicine that belongs to the tyrosine kinase inhibitor family. Cabozantinib works by blocking several receptor tyrosine kinases involved in cancer-cell signalling, tumour growth, invasion and the development of new blood vessels that can support tumour progression.
Depending on the specific regulatory approval and formulation, cabozantinib is used in several oncology settings, including certain cases of advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid carcinoma and neuroendocrine tumours. Treatment selection depends on the cancer type, previous therapy, disease stage and the applicable local prescribing information.
The 80 mg strength should not automatically be interpreted as the standard daily dose for every patient. Cabozantinib dosing varies according to the indication, formulation and whether it is being used alone or with another anticancer medicine. Dose adjustments may also be required if significant adverse reactions occur.
Because cabozantinib is a prescription cancer medicine with potentially serious adverse effects and clinically important drug interactions, it should be used under the supervision of an appropriately qualified oncology professional.
How Does Cabozantinib Work?
Cabozantinib is a multi-target tyrosine kinase inhibitor. Cancer cells and the surrounding tumour environment use signalling pathways that can promote cellular growth, survival, migration and angiogenesis.
Cabozantinib inhibits several receptor tyrosine kinases, including pathways involving VEGFR, MET, AXL and RET.
A simplified mechanism is:
Receptor signalling → tumour-cell growth and survival → angiogenesis → tumour progression
Cabozantinib interferes with selected signalling pathways:
Cabozantinib → kinase inhibition → reduced growth signalling + reduced angiogenic signalling → suppression of tumour progression
VEGFR inhibition can interfere with the signalling involved in formation of new blood vessels. MET and AXL pathways are also associated with tumour-cell behaviour, survival and resistance mechanisms in certain cancers. By affecting multiple pathways simultaneously, cabozantinib provides a targeted approach to treating selected advanced malignancies.
It is important to understand that cabozantinib does not work in the same way as traditional cytotoxic chemotherapy. Its therapeutic activity comes from blocking specific molecular signals involved in cancer biology.
Uses & Therapeutic Applications
Cabozantinib is used in specific oncology settings, which may vary by country and formulation.
Renal Cell Carcinoma
Cabozantinib is used for certain adults with advanced renal cell carcinoma (RCC), including specific treatment settings after previous therapy and, for some approved regimens, in combination with nivolumab.
Hepatocellular Carcinoma
It may be prescribed for selected adults with hepatocellular carcinoma (HCC) who have previously received sorafenib.
Differentiated Thyroid Carcinoma
Cabozantinib is used in certain adults with advanced or metastatic differentiated thyroid cancer following previous systemic treatment when the disease meets the relevant treatment criteria.
Neuroendocrine Tumours
Certain approved indications also include selected adults with unresectable or metastatic, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumours after previous systemic therapy.
Dosage & Administration
The appropriate cabozantinib dose must be determined by the treating oncologist.
For some approved Cabometyx tablet indications, standard adult regimens use doses such as 60 mg once daily, while the dose may differ when cabozantinib is combined with nivolumab. Therefore, the presence of an 80 mg strength does not mean that 80 mg once daily is appropriate for every patient.
Patients should:
- Follow the exact prescription provided by their oncology specialist.
- Take cabozantinib consistently according to the instructions for the prescribed formulation.
- Avoid changing the dose without medical advice.
- Follow the specific food-related instructions supplied with the product.
- Do not double a dose after a missed dose unless specifically instructed by a healthcare professional.
Dose interruption or reduction may be necessary when clinically significant adverse reactions occur.
Common Side Effects
Possible adverse effects include:
- Diarrhea
- Fatigue
- Nausea
- Reduced appetite
- Vomiting
- Weight loss
- High blood pressure
- Hand-foot syndrome
- Abdominal discomfort
- Changes in laboratory test results
Serious Side Effects
Potentially serious complications may include:
- Severe bleeding
- Gastrointestinal perforation or fistula
- Severe diarrhea
- Blood clots
- Very high blood pressure
- Serious liver problems
- Wound-healing complications
- Severe skin reactions
- Jaw osteonecrosis in susceptible patients
Patients experiencing severe or unusual symptoms should contact their healthcare professional promptly.
Important Precautions
Before treatment, the doctor should be informed about:
- Previous bleeding problems
- High blood pressure
- Liver disease
- Kidney disease
- Recent or planned surgery
- Cardiovascular disease
- Current medicines
- Herbal or nutritional supplements
- Dental problems or planned invasive dental procedures
Cabozantinib may affect wound healing, blood pressure and bleeding risk, so these factors can be particularly important during treatment planning.
Drug Interactions
Cabozantinib can interact with medicines that affect its metabolism, particularly drugs influencing CYP3A4 activity.
Patients should provide their doctor with a complete list of:
- Prescription medicines
- Over-the-counter medicines
- Vitamins
- Herbal products
- Traditional medicines
- Nutritional supplements
Strong CYP3A4 inhibitors or inducers may require avoidance, dose consideration or closer monitoring.
For the specific cabozantinib formulation, follow the applicable prescribing information regarding food administration.
Pregnancy & Breastfeeding
Cabozantinib may cause fetal harm. Patients who are pregnant, planning pregnancy or capable of becoming pregnant should discuss treatment and contraception with their healthcare professional.
Breastfeeding should be avoided during treatment when required by the applicable prescribing information. Patients should discuss breastfeeding plans with their oncology team before starting therapy.
Storage Instructions
Store CABOXEN-80MG according to the storage conditions printed on its packaging.
General precautions:
- Keep the medicine in its original container.
- Protect it from excessive heat and moisture.
- Keep it away from direct environmental exposure where applicable.
- Store out of reach of children.
- Do not use capsules that appear damaged or altered.
- Follow the manufacturer's labelled storage requirements.
Frequently Asked Questions
What is CABOXEN-80MG?
CABOXEN-80MG contains cabozantinib, a targeted tyrosine kinase inhibitor used in selected cancer-treatment settings.
What is cabozantinib used for?
Cabozantinib is used for certain advanced cancers, including specific forms of kidney, liver, thyroid and neuroendocrine cancers depending on regulatory approval.
Is cabozantinib chemotherapy?
Cabozantinib is a targeted tyrosine kinase inhibitor rather than conventional cytotoxic chemotherapy.
How does cabozantinib work?
It blocks several receptor tyrosine kinase pathways involved in tumour growth, signalling and angiogenesis.
What are common cabozantinib side effects?
Diarrhea, fatigue, nausea, reduced appetite, hypertension and hand-foot syndrome are among commonly reported adverse effects.
Can cabozantinib cause high blood pressure?
Yes. Hypertension is a recognized adverse effect and blood pressure may require regular monitoring.
Can cabozantinib cause diarrhea?
Yes. Diarrhea is relatively common and can become severe in some patients.
Can cabozantinib cause bleeding?
Serious bleeding is a recognized risk. Unusual or significant bleeding should receive prompt medical attention.
Is CABOXEN-80MG the standard cabozantinib dose?
Not necessarily. Cabozantinib dosing depends on the indication, formulation, combination therapy and individual patient factors.
Can cabozantinib cure cancer?
It should not be described as a guaranteed cure. It is intended to treat or control specific cancers in appropriately selected patients.
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides pharmaceutical information and specialty-medicine support for individuals and organizations seeking information about prescription and high-value medicines.
Our information resources can cover:
- Oncology medicines
- Targeted cancer therapies
- Kidney cancer treatments
- Liver cancer treatments
- Thyroid cancer treatments
- Neuroendocrine tumour medicines
- Prescription medicine information
- International medicine information
RootAid Pharma does not claim to manufacture CABOXEN-80MG or cabozantinib. Availability, prescription requirements, import regulations and medicine-access rules can differ between countries.
Medical Disclaimer
This content is provided for educational and informational purposes only. It does not replace professional medical advice, diagnosis, prescribing information or individualized cancer treatment.
Cabozantinib is a prescription medicine. The correct dose and treatment schedule must be determined by a qualified healthcare professional based on the cancer type, treatment history, formulation and patient's clinical condition.
Do not start, stop, or change cabozantinib treatment without medical advice.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.